Agadir – Moroccan pharmaceutical group Laprophan is preparing to expand its manufacturing capacity with a new sterile injectable drugs facility in Ain El Aouda, near Rabat, scheduled to begin operations in 2027 following a MAD 374 million ($38.1 million) investment.
The facility, developed through Laprophan subsidiary Amanys Pharma, will have an annual production capacity of around 30 million consumer sales units (CSU). The project is part of the group’s efforts to strengthen its pharmaceutical manufacturing capabilities and serve growing demand in Morocco and international markets.
Built over an area of 18,000 square meters, the highly automated plant will manufacture injectable medicines packaged in vials and flexible bags. It also includes storage facilities capable of accommodating up to 7,000 pallets, within an industrial complex covering 62,000 square meters.
The company designed the facility to comply with European Good Manufacturing Practice (EU-GMP) standards, which govern pharmaceutical production and quality control.
The facility will initially focus on large-volume injectable medicines, with plans to expand production to small-volume injectables at a later stage.
Laprophan acquired full ownership of Amanys Pharma in 2024 through AIF Pharma Maroc, bringing together their respective activities as part of a broader strategy to strengthen the group’s position across specialized pharmaceutical segments.
Beyond the sterile injectables project, the Ain El Aouda industrial complex includes a separate facility producing solid oral beta-lactam antibiotics.
The unit covers 7,300 square meters and currently produces around 15 million units annually. The company expects to increase its capacity to approximately 25 million units by 2027. Its storage facilities can accommodate 2,000 pallets.
Amanys Pharma specializes in pharmaceutical manufacturing, imports, distribution, and exports. The company is also among Morocco’s leading beta-lactam producers, with an established presence in the hospital market and expertise in anti-infectives, intensive care, hematology, and specialized oncology.
